RxDoctor Payments Data

William Suozzi, MD

Internal Medicine · New York, NYNPI 1386663235

Payments from drug & device makers

$7,254in general payments, 2019–2025

Across 359 payments — averaging $20.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$973
  • Lundbeck LLC$673
  • GSK$667
  • Gilead$589
  • AstraZeneca$550
  • plus $3K from 23 others

What the payments were for

  • Food & beverage$7,248100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,254 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$83,855
Medicare patients
331
Services billed
1,351

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban61$80,498
MounjaroTirzepatide53$76,144
CreonLipase/Protease/Amylase14$40,492
JardianceEmpagliflozin20$27,474
XareltoRivaroxaban14$25,193
FarxigaDapagliflozin Propanediol18$23,842
JanuviaSitagliptin Phosphate19$19,136
MyrbetriqMirabegron13$10,896
SynthroidLevothyroxine Sodium102$6,212
Mesalamine16$5,044
Rosuvastatin Calcium292$4,284
Atorvastatin Calcium313$3,879
Ezetimibe81$3,469
Famotidine132$3,289
Pulmicort FlexhalerBudesonide11$2,933

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$244$81,92789 claims
Lilly USA, LLCMounjaro$404$76,14453 claims
AbbVieCreon, Synthroid$973$46,704116 claims
Boehringer IngelheimJardiance$390$27,47420 claims
AstraZenecaFarxiga, Pulmicort Flexhaler$550$26,77629 claims
Johnson & JohnsonXarelto$25$25,19314 claims
MerckJanuvia$133$19,13619 claims
Astellas Pharma US IncMyrbetriq$144$10,89613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →